← All trials
NCT01457495
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1998
- Primary completion
- Sep 1, 1999
- Completion date
- Sep 1, 1999
- First posted
- —
- Last posted
- —
- Enrollment
- 312
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- hepatitis b vaccine (recombinant)
- hepatitis b vaccine (recombinant)
- haemophilus influenzae type b conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- Inactivated polio virus - Enhanced
- Inactivated polio virus - Enhanced
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.